Komori
Semi-Annual Report4579RaQualia Pharma Inc.Pharmaceuticals

Semi-Annual Report — FY2026 H1

What RaQualia Pharma Inc. reported for the period from 2026-01-01 to 2026-12-31. Filed by ラクオリア創薬株式会社

How much it says
72Detailed
What moved here
26named for the first time
Its own wording
33terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period from 1 January to 30 June 2026, sales of the marketed human pharmaceutical tegoprazan performed well, and the filing describes progress in the product’s rollout across countries, clinical trial results, and approval and application status. In addition, effective 1 January 2026, the company absorbed Temrick Co., Ltd., a consolidated subsidiary, and excluded it from the scope of consolidation.

Komori's summary of this document, not the document's own words.
72Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
Magnitude of change
61
Detailed
Strategic shift
88
Very detailed
Capital movements
75
Very detailed
Disclosure Gaps
100
Very detailed
Future commitments
68
Detailed
Change in Risk
55
Typical
Financial and Capital Policy
53
Typical
Product Portfolio
35
Thin
Technology Position
73
Detailed
Confidence in Strategic Bets
R&D spend9億円Money spent making new things.
Cash left over3億円Cash from the business, less what went into equipment.
Spent on equipment22百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
RaQualia Pharma Inc. — FY2026 H1 | Komori